Clinuvel Pharmaceuticals (CUV)

mercado OTC
Valores en USD
6,9000
0,0000(0,00%)
Mercado cerrado

Cuenta de resultados CLVLF

Estado de resultados avanzada
Período terminado:
2015
30/06
2016
30/06
2017
30/06
2018
30/06
2019
30/06
2020
30/06
2021
30/06
2022
30/06
2023
30/06
2024
30/06
Ingresos totales
aa.aaaa.aaaa.aaaa.aaaa.aa32,5748,3265,7278,3288,18
Crecimiento de los ingresos totales
aa.aaaa.aaaa.aaaa.aaaa.aa+4,89%+48,37%+36,02%+19,17%+12,59%
Coste de los ingresos
aa.aaaa.aaaa.aaaa.aaaa.aa7,34,179,257,527,73
Beneficio bruto
aa.aaaa.aaaa.aaaa.aaaa.aa25,2644,1556,4770,880,45
Crecimiento del beneficio bruto
aa.aaaa.aaaa.aaaa.aaaa.aa-17,44%+74,73%+27,92%+25,37%+13,62%
Margen de beneficio bruto %
aa.aaaa.aaaa.aaaa.aaaa.aa77,58%91,36%85,92%90,4%91,23%
Total de otros gastos operativos
aa.aaaa.aaaa.aaaa.aaaa.aa13,0115,5820,9226,6731,88
Crecmiento total de otros gastos operativos
Gastos de I+D
Gastos de venta, generales y administrativos
Otros gastos operativos
aa.aaaa.aaaa.aaaa.aaaa.aa-6,45%+19,7%+34,32%+27,48%+19,5%
aa.aaaa.aaaa.aaaa.aaaa.aa0,340,551,231,272,35
aa.aaaa.aaaa.aaaa.aaaa.aa12,2314,1719,1524,6428,95
aa.aaaa.aaaa.aaaa.aaaa.aa---0,22-0,02-0,56
Margen neto
aa.aaaa.aaaa.aaaa.aaaa.aa12,2528,5735,5544,1348,57
Crecimiento del margen neto
aa.aaaa.aaaa.aaaa.aaaa.aa-26,6%+133,19%+24,43%+24,14%+10,07%
Margen EBIT %
aa.aaaa.aaaa.aaaa.aaaa.aa37,62%59,12%54,09%56,34%55,08%
Gastos netos por intereses
aa.aaaa.aaaa.aaaa.aaaa.aa-1,49-1,62-1,830,712,87
Crecimiento de gastos netos por intereses
aa.aaaa.aaaa.aaaa.aaaa.aa-374,32%-8,54%-13,09%+138,96%+302,53%
Total de gastos de intereses
aa.aaaa.aaaa.aaaa.aaaa.aa-2,05-1,62-2,27-3,19-4,45
Ingresos por intereses e inversiones
aa.aaaa.aaaa.aaaa.aaaa.aa0,56-0,443,917,32
Total de otros gastos no operativos
aa.aaaa.aaaa.aaaa.aaaa.aa0,65-1,370,60,74-0,76
EBT excepto elementos no habituales
aa.aaaa.aaaa.aaaa.aaaa.aa11,4125,5834,3245,5850,68
Ganancia (pérdida) de la venta de activos
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Total de otras partidas no habituales
aa.aaaa.aaaa.aaaa.aaaa.aa0,130,13---
EBT incluyendo las partidas inusuales
aa.aaaa.aaaa.aaaa.aaaa.aa11,5425,7134,3245,5850,68
Crecimiento del EBT incluidas las partidas inusuales
aa.aaaa.aaaa.aaaa.aaaa.aa-36,29%+122,8%+33,48%+32,8%+11,19%
Margen del EBT incluidas las partidas inusuales
aa.aaaa.aaaa.aaaa.aaaa.aa35,44%53,22%52,22%58,19%57,47%
Impuesto sobre la renta
aa.aaaa.aaaa.aaaa.aaaa.aa-3,510,9813,4414,9715,04
Beneficios netos para la empresa
aa.aaaa.aaaa.aaaa.aaaa.aa15,0524,7320,8830,635,64
Intereses minoritarios
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Beneficio neto
aa.aaaa.aaaa.aaaa.aaaa.aa15,0524,7320,8830,635,64
Crecimiento del beneficio neto
aa.aaaa.aaaa.aaaa.aaaa.aa-17%+64,29%-15,57%+46,58%+16,44%
Margen del beneficio neto %
aa.aaaa.aaaa.aaaa.aaaa.aa46,22%51,18%31,77%39,08%40,41%
Dividendo preferente y otros ajustes
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Beneficio neto sobre ingresos ordinarios
aa.aaaa.aaaa.aaaa.aaaa.aa15,0524,7320,8830,635,64
BPA básico: Crecimiento de actividades continuadas
aa.aaaa.aaaa.aaaa.aaaa.aa0,310,50,420,620,72
BPA básico: crecimiento de actividades continuadas
aa.aaaa.aaaa.aaaa.aaaa.aa-18,8%+63,79%-15,57%+46,58%+15,45%
BPA diluido: Crecimiento de actividades continuadas
aa.aaaa.aaaa.aaaa.aaaa.aa0,30,480,40,590,7
BPA diluido: Actividades continuadas
aa.aaaa.aaaa.aaaa.aaaa.aa-18,58%+62,42%-16,74%+46,65%+18,11%
Promedio ponderado básico de acciones en circulación
aa.aaaa.aaaa.aaaa.aaaa.aa49,2649,4149,4149,4149,83
Promedio ponderado diluido de acciones en circulación
aa.aaaa.aaaa.aaaa.aaaa.aa50,4651,1351,7851,8251,03
Dividendo por acción
aa.aaaa.aaaa.aaaa.aaaa.aa0,030,030,040,050,05
Crecimiento del dividendo por acción
aa.aaaa.aaaa.aaaa.aaaa.aa0%0%+60%+25%0%
EBITDA
aa.aaaa.aaaa.aaaa.aaaa.aa12,4229,0735,9744,5249,32
Crecimiento del EBITDA
aa.aaaa.aa